Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)

You may also be interested in...



Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer

NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said

Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer

NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said

India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry

NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases

Related Content

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel